Clinical Publications

Our medicines and pipeline are supported by scientific, peer-reviewed publications that reinforce the value of the therapeutics we develop.

FEATURED PUBLICATION

Body diagram showing various types of pain

Sallee FR, Palumbo DR, Abbas R, Berry SA, Puthili SP, Kathala KK. Effect of food intake on the pharmacokinetics of a novel methylphenidate extended-release oral suspension for attention deficit hyperactivity disorder. Clin Pharmacol Drug Dev. 2017;6(5):47

VIEW ON WEBSITE

Methylphenidate Extended-Release Oral Suspension

Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB. Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J Atten Disord. 2017;21(14):1180-1191.
Sallee FR, Palumbo DR, Abbas R, Berry SA, Puthili SP, Kathala KK. Effect of food intake on the pharmacokinetics of a novel methylphenidate extended-release oral suspension for attention deficit hyperactivity disorder. Clin Pharmacol Drug Dev. 2017;6(5):47
Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol.
Childress AC, Sallee FR, Berry SA. single-dose pharmacokinetics of nwp06, an extended-release methylphenidate suspension, in children and adolescents with ADHD. Postgrad Med. 2011;123(5):80-88.
Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010;122(5):35-41.

Methylphenidate Extended-Release Tablet

Amphetamine Extended-Release Oral Suspension

Full, Dual Nociceptin/Orphanin FQ Peptide (NOP) Receptor and µ-Opioid Peptide (MOP) Receptor (Dual-NMR) Agonist

Please see Full Prescribing Information and Medication Guide for Dyanavel XR, Quillivant XR and QuilliChew ER, including Boxed Warning about Abuse and Dependence.

DYANAVEL is a registered trademark of Tris Pharma, Inc. Quillivant XR and QuilliChew ER are registered trademarks of NextWave Pharmaceuticals, Inc. NextWave Pharmaceuticals, Inc. is a wholly owned subsidiary of Tris Pharma, Inc.

Clinical Publications

Our medicines and pipeline are supported by scientific, peer-reviewed publications that reinforce the value of the therapeutics we develop.

Sallee FR, Palumbo DR, Abbas R, Berry SA, Puthili SP, Kathala KK. Effect of food intake on the pharmacokinetics of a novel methylphenidate extended-release oral suspension for attention deficit hyperactivity disorder. Clin Pharmacol Drug Dev. 2017;6(5):47

VIEW ON WEBSITE<img width="24" height="24" decoding="async" src="/wp-content/uploads/2023/07/arrow_back.png" alt="Arrow Icon" />

Our medicines and pipeline are supported by scientific, peer-reviewed publications that reinforce the value of the therapeutics we develop.

VIEW ON WEBSITE